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ABSTRACT 
Quantitative structure–activity relationship study using principal component artificial neural network (PC-ANN) 
methodology was conducted to predict the inhibitory activities expressed as pIC50 of 73 non-tri cyclic cyclooxygenase-2 
(COX-2) inhibitors. The results obtained by MLR shows that the best two models are close to each other with regression 
coefficient of 0.85.  These optimal models were further analyzed by PC-ANN and the best model obtained was with 
regression coefficient of 0.823 for the test set. The lowest prediction sum of squares   (PRESS) value obtained for the 
prediction set is 4.727 which accounts for predictability of the model. Artificial neural networks provide improved models 
for heterogeneous data sets without splitting them into families. Both the external and cross-validation methods are used 
to validate the performances of the resulting models. Randomization test is employed to check the suitability of the 
models. 
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1. INTRODUCTION  
Cyclooxygenase-2 (COX-2) inhibition has been one of the most investigated areas of research in the most recent decade 
owing to its essential role in relieving pain and other inflammatory conditions. Non-steroidal anti-inflammatory drugs 
(NSAIDs) are deeply used in the treatment of wide variety of inflammatory conditions.  NSAIDs are anti-pyretic,  analgesic 
activities  and are prescribed as first choice  in the treatment of arthritis, rheumatisms and other degenerative of 
inflammatory joint disease as well as reliving the pains of everyday life. From a historical point of view, the first NSAID with 
therapeutic benefits was aspirin, which has now been used for more than 100 years as a NSAID. However, these drugs 
are associated with high risk of gastrointestinal and renal adverse effects. NSAIDs act by inhibition of cyclooxygenase 
(COX), the enzyme involved in the biosynthesis of prostaglandins and prostacyclins  from arachidonic acid. Prostaglandins 
are involved in physiological functions such as protection of the stomach mucosa, aggregation of platelets and regulation 
of kidney function. They also have pathological functions such as their involvement in inflammation, fever and pain. 
Cyclooxygenase exists in at least two isoforms, namely, the constitutive cyclooxygenase-1 (COX-1) and the inducible 
cyclooxygenase-2 (COX-2). Inhibition of COX-1 is accountable for the adverse gastrointestinal and renal effects of 
NSAIDs while the inhibition of COX-2 accounts for NSAIDs therapeutic effects. All classical NSAIDs, such as aspirin and  
ibuprofen  can inhibit both COX-1 and COX-2, but bind more strongly to COX-1. Selective COX-2 inhibitors have the same 
anti-inflammatory, anti-pyretic, and analgesic activities as do nonselective NSAIDs but without causing gastric ulceration, 
bleeding and perforation.  
Increasing selectivity for COX-2 also increased toxicity, since the anti-thrombotic prostacyclin is formed by COX-2 and 
inhibiting its synthesis precipitated heart attacks. The problem of this side action has not yet been resolved. Is it possible 
to obtain the benefit of low gastrotoxicity and avoid the danger of a heart attack? Perhaps lumiracoxib has provided the 
solution. However, it now appears that by taking any NSAID, patients risk experiencing a heart attack [1-6]. The review [7] 
provides the various structural classes of selective COX-2 inhibitors with special emphasis on their structure activity 
relationships. In this study, we concentrate on Non-Tricyclic compounds which lack the cyclic central core and have 
monocyclic or bicyclic structures. 
The importance of developing selective COX-2 inhibitors is manifested by the deep efforts dedicated in this field that 
resulted in the synthesis of hundreds of compounds, which displayed activity against COX-2.  In this study, we are 
concerned in designing a new set of COX-2-selective inhibitors based on simple but statistically sound Quantitative 
Structure Activity Relationship (QSAR) models whose parameters can be easily obtained by means of commonly available 
and less costly computational programs. 
Quantitative structure activity relationship (QSAR) is the quantitative correlation of structural properties of a compound 
with its chemical, physical, pharmaceutical, or biological effect.  Based on this assumption, many trials were made to 
correlate various physicochemical properties of a set of molecules with their experimentally known biological activity, and 
so QSAR goals are: (1) Prediction of the activity of untested molecules, depending on models developed using a series of 
molecules and (2) Constructing ideas about mechanism of action of a group of compounds leading to a design of new 
compounds of better activity and less toxicity. QSAR model development process is typically divided into three steps: data 
preparation, data analysis and model validation.  
Data preparation starts by selection of the data set to be used; this may simply be the extraction of data from a database 
or may need additional experimental studies. There are two steps to complete data preparation: geometry optimization 
and descriptors calculation. Geometry optimization or minimization is finding the coordinates that represents the potential 
energy minimum for the molecular structure in its 3D form. Theoretical molecular descriptor is a value that describes the 
molecular structure numerically.  These descriptors can be simple such as molecular weight or complex such as 
geometrical descriptors.  
In data analysis, the first step is to decide which techniques for statistical analysis and correlation to be used. If our 
correlation models to be built are linear then we use multilinear regression (MLR) or non linear then we use artificial neural 
network (ANN). 
Model validation is the final part of the model development process, the predictive power of the model is tested on an 
independent set of compounds, generally predictive power is the most important characteristics of the model and model 
predictivity is the ability of the model to predict accurately the target activity of a compound that was not used for model 
development. 
In model validation step, most of validation processes implement the leave one out (LOO) and leave many out (LMO) 
cross-validation procedures.  The most common outcome parameters resulted from cross-validation procedures are cross-
validated determination coefficient q
2
 (R
2
cv) and root mean squares error (RMSE). High R
2
cv and low RMSE values is a 
result of good and more predictive model  and that lead to better description of the observed data.   
Multilinear regression (MLR) is multivariate statistical technique to examine the linear relationship between the single 
dependent variable (activity) and two or more independent variables (molecular descriptors). Collinearity, which often 
exists between independent variables, generates a severe problem in certain types of mathematical handling such as 
matrix inversion [8]. As it was recently reviewed by Schneider and Wrede [9], the flexibility of ANN for finding out 
relationships that are more complex allows this method to be widely applied in QSAR studies. Both linear and nonlinear 
mapping functions can be modeled by configuring the network properly. To obtain powerful and accurate ANN models, 
one should train a subset of descriptors instead of all generated descriptors [10–15].  
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Billones et al. [16] performed QSAR study of COX-2 inhibitors belonging to nine chemical classes using semi-empirical 
(AM1) computed quantum mechanical descriptors and electrotopological sate (E-state) indices. Another study was 
performed by Gupta  et al, [17] related to 3D-QSAR of some tetrasubstituted pyrazoles as COX-II inhibitors, a six point 
pharmacophore with 3 hydrogen bond acceptors, one hydrophobic group and two aromatic rings as pharmacophoric 
feature was developed.  
 
This study aims to predict the inhibitory activity pIC50 of the data set in reference [18-25] as one group without splitting 
them into categorizes. This is achieved by applying ANN to develop new statistically validated QSAR models utilizing 
different types of descriptors. The strength and the predictive performance of the proposed models were verified using 
cross validation, chance correlation and external test set. Therefore, the motivation of this work is to provide QSAR 
models that will be used to predict inhibitory activity of unknown compounds and also these models may be used to design 
new drugs. 
2. MATERIALS AND METHODS  
2.1 Software 
Geometry optimizations were performed using HyperChem (Version 7.5; Hypercube, Inc, USA, http://www.hyper.com) at 
the AM1 level of theory. An AM1 optimization was chosen because it was developed and parameterized for common 
organic structures. Descriptors were calculated using HyperChem and DRAGON (Milano Chemometrics and QSAR 
Group, USA,
 
evaluation
 
version 5.0, http://www.disat.unimib.it/vhml) software. SPSS
 
software (version 13.0, SPSS, Inc.) 
was used for the simple MLR analysis while ANN analysis was performed using MATLAB (Version 7.0.1 (R14), 
http://www.mathworks.com).  
2.2 Chemical data and descriptors 
 A data set of 73non-tricyclic  COX-2 inhibitors and their inhibitory activity (pIC50) were obtained from reference [18-25] 
and used in this study. These inhibitors and their inhibitory activities are included in Table S1 in the supporting information.  
The structures of the compounds are drawn by hyperchem software. The resultant structures are 2D then we convert them 
to 3D. HyperChem software was used to optimize the different compound structures using AM1 semi-empirical level. The 
optimization was preceded by the Polak-Rebiere algorithm. To be sure that we reached global minima, geometry 
optimization was run multiple times with different starting points for each molecule.   
In this study, a pool of 1481 descriptors classified into 18 different groups was calculated using Dragon software. The 
constant or nearly constant descriptors for all the 73 compounds were discarded from further analysis. Furthermore, 
chemical descriptors such as HOMO, LUMO and polarizability were calculated using HyperChem software. Depending on 
the HOMO and LUMO values, electrophylicity, electronegativity, hardness, and softness descriptors were calculated. 
Other descriptors such as surface area approximate, surface area grid, volume, mass, polarizability, hydration energy, 
octanol-water partition coefficient (logP), and refractivity were calculated. Discarding highly inter-correlated (r>0.95) 
descriptors and following the procedure described in the next section, this number of descriptors was declined to 14 
descriptors in the "final" MLR regression model (model 14 in Table 1).  
2.3 Multiple linear regression (MLR) analysis 
Multiple linear regression analysis with stepwise selection and elimination of variables was employed to model the 
inhibitory activity (pIC50) relationships with each group of descriptors separately. Log1/IC50 is the dependent variable and 
the set of descriptors as independent variables. Then, the ―optimal‖ descriptors for each group were selected and gathered 
in one group to perform new MLR analysis. 
2.4 Principal components analysis (PCA) 
Collinear descriptors add redundancy to the input data matrix and consequently the performances of the models obtained 
by using these descriptors would be degraded. PCA and more specifically factor analysis, groups together variables that 
are collinear to form a composite indicator capable of capturing as much of common information of those indicators as 
possible. Each factor reveals the set of variables with the highest relationship. The idea under this approach is to explain 
the highest possible variation in the indicators set using the smallest possible number of factors. Consequently, the index 
no longer depends upon the dimensionality of the data set but it is rather based on the 'statistical' dimensions of the data. 
Application of PCA on a descriptor data matrix results in a loading matrix containing factors or PCs, which are orthogonal 
and therefore have no correlation with each other.  
The PC‘s were calculated by singular value decomposition (SVD) method in MATLAB environment (MathWork Inc. 
Version 7.0.1 (R14)). Due to the quality of data, a previous treatment of the data is essential before applying the 
multivariate analysis methods. Scaling and centering is one of the pre-processing methods needed before performing the 
regression methods joint with feature extraction. Projection methods results depend on the normalization of the data. 
Descriptors with small absolute values have a small contribution to overall variances leading to biased PC‘s caused by the 
presence of other descriptors with higher values. In order to have the focus on the important variables in the model, equal 
weights are assigned to each descriptor, with appropriate scaling. Furthermore, descriptors were standardized to unit 
variance and zero mean (autoscaling) to give all variables the same importance. Then, the data matrix containing the 
entire set of descriptors and activity were simultaneously subjected to PCA. 
    ISSN 2321-807X 
3338 | P a g e                                                    D e c e m b e r  2 4 ,  2 0 1 4  
2.5 Principal component-artificial neural network (PC-ANN) analysis 
ANNs are computer-based models in which a number of nodes, also called neurons are interconnected by links forming 
netlike structure ‗‗layers.‘‘ A variable value is assigned to every neuron. 
There are three kinds of neurons: (a) the input neurons which receive their values from independent variables and 
constitute the input layer, (b) the hidden neurons which collect values from other neurons, giving a result that is passed to 
a successor neuron, (c) the output neurons which take values from other units and correspond to different dependent 
variables, forming the output layer. In this sense, network architecture is commonly represented as I–H–O, where I, H, and 
O are the number of neurons in the input, hidden, and output layers, respectively. 
The weights are links between units that condition the values assigned to the neurons. The weights are adjusted through a 
training process in order to minimize network error. For this, a non-linear transfer function relates the input parameters 
with the outputs. Commonly neural networks are adjusted, or trained, so that a particular input leads to a specific target 
output. 
In PC-ANN analysis, as a preliminary treatment, the input data (i.e., molecular descriptors) were normalized to have zero 
mean and unity variance, and then were subjected to PCA before being introduced into the neural network. It should be 
illustrated that for each MLR resulted model, separate ANN models were developed so that the input's descriptors were 
the subsets selected by the stepwise MLR methods. In the case of each MLR model, a feed-forward neural network with 
back-propagation of error algorithm was constructed to model the activity–structure relationships between the descriptors 
on one hand and inhibitory activity on the other hand. The model development in ANN and the network architecture is fully 
described by us [13] and others [14]. The data set was divided into three subsets: training, validation and external test 
sets. The training and the validation sets are the norm in all model training processes. The test set is used to test the trend 
of the prediction precision of the model trained at some point of the training evolution. The extracted PC‘s for each MLR 
model were classified homogenously, based on the factors space of the descriptors, into training set (60%), validation set 
(20%) and external test set (20%) according to the PCA and the first two PC‘s were plotted against each other (see Figure 
1). Afterward, the training set was used to optimize the network performance. The regression between the network output 
and the observed activity was calculated for each set individually. The training function 'trainscg' was used to train the 
network. To find models with lower errors, the ANN algorithm was run many times, with different geometry and initial 
weights each time. 
 
Figure 1. First and second principal components for the factor spaces of the descriptors and non-tricyclic COX-2 
inibitory activity data. 
 
 
 
    ISSN 2321-807X 
3339 | P a g e                                                    D e c e m b e r  2 4 ,  2 0 1 4  
3. RESULTS AND DISCUSSION  
3.1 MLR analysis 
In continuation to recent QSAR studies [26-29] done using similar methods, we developed an ANN-QSAR model that 
describes the inhibitory activity of a series of compounds using large number of different descriptors. MLR were performed 
on each one of the  groups of descriptors individually (individual approach described in Ref. [30] by Deeb) where pIC50 is 
the dependent variable. Stepwise method is used to develop multilinear equation by correlating dependent variable 
(activity) and the best independent variables. 
Next, a new or ―final‖ MLR analysis was performed by correlating the dependent variable (activity) and the optimal 
descriptors selected from the individual MLR models. Table 1 shows the regression models suggested from the ―final‖ 
MLR analysis. The number of descriptors in these models is varied between 1 and 14. Model 14 and 15 are close to each 
other with one descriptor less. The highest coefficient of determination (R
2
) obtained, is 0.720 for a regression model with 
14 descriptors (model 14). Table 2 shows a key for the different descriptors used in the final MLR model. 
 
Table 1. Final MLR model summary. 
Model 
No. 
R R
2 
Adjusted R
2 
SE Descriptors 
1 0.331 0.109 0.097 0.776 MATS3e 
2 0.429 0.184 0.161 0.748 MATS3e, E1v 
3 0.533 0.284 0.253 0.705 MATS3e, E1v, E3s 
4 0.631 0.398 0.363 0.652 MATS3e, E1v, E3s, Me 
5 0.676 0.457 0.417 0.624 MATS3e, E1v, E3s, Me, C-028 
6 0.707 0.499 0.454 0.604 MATS3e, E1v, E3s, Me, C-028, G3p 
7 0.726 0.527 0.476 0.591 MATS3e, E1v, E3s, Me, C-028, G3p, BELm3 
8 0.755 0.570 0.516 0.568 MATS3e, E1v, E3s, Me, C-028, G3p, BELm3, Mor03u 
9 0.770 0.593 0.535 0.557 MATS3e, E1v, E3s, Me, C-028, G3p, BELm3, Mor03u, G2u 
10 0.785 0.616 0.554 0.545 MATS3e, E1v, E3s, Me, C-028, G3p, BELm3, Mor03u, G2u, 
MATS8e 
11 0.799 0.639 0.573 0.534 MATS3e, E1v, E3s, Me, C-028, G3p, BELm3, Mor03u, G2u, 
MATS8e, dipole moment (Debyes) 
12 0.822 0.675 0.611 0.51 MATS3e, E1v, E3s, Me, C-028, G3p, BELm3, Mor03u, G2u, 
MATS8e, dipole moment (Debyes), G3m 
13 0.837 0.700 0.634 0.494 MATS3e, E1v, E3s, Me, C-028, G3p, BELm3, Mor03u, G2u, 
MATS8e, dipole moment (Debyes), G3m, H7m 
14 0.849 0.720 0.652 0.482 MATS3e, E1v, E3s, Me, C-028, G3p, BELm3, Mor03u, G2u, 
MATS8e, dipole moment (Debyes), G3m, H7m, R6m 
15 0.848 0.719 0.657 0.478 MATS3e, E1v, E3s, Me, C-028, G3p, BELm3, Mor03u, G2u, 
dipole moment (Debyes), G3m, H7m, R6m 
 
The following equation represents the best MLR model (model 15) with 13 descriptors: 
pIC 50   = -7.938 (±11.143) - 2.987 (±1.328) × “MATS3e” + 7.043 (±1.705) × “E1v” + 2.967 (±0.727) × E3s -17.669 
(±8.819) × “Me” + 0.424 (±0 .167) × “C-028” + 21.414 (±5.236) × “G3p” + 7.092 (±1.299) × “BELm3” + 0 .182 (±0.095) 
× “Mor03u” + 28.858 (±8.360) × ―G2u” + 0 .179 (±0.057) × “dipole moment (Debyes)” + 46.973 (±12.190) × “G3m” - 
4.845 (±1.268) × “H7m” +  1.783 (±0.705) × ―R6m” 
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According to the above equation, the most important descriptor in this equation is G3m which is related to the 3rd 
component symmetry directional WHIM index / weighted by mass; it is directly proportional to the activity of the 
compounds. The second important descriptor is G2u which is related to 2nd component symmetry directional WHIM index 
/ unweighted; it is directly proportional to the activity of the compounds.  
 
Table 2. Key for the different descriptors used in the final MLR model. 
Descriptor symbol  
 
Description  
MATS3e Moran autocorrelation of lag 3 weighted by Sanderson electronegativity 
E1v 1
st
 component accessibility directional WHIM index / weighted by van der waals volume 
E3s 3
rd
 component accessibility directional WHIM index / weighted by I-state 
Me Mean atomic Sanderson electronegativity (scaled on Carbon atom) 
C-028 R—CR—X (Atom-centred fragment) 
G3p 3
rd
 component symmetry directional WHIM index / weighted by polarizability 
BELm3 lowest eigenvalue n. 3 of Burden matrix / weighted by atomic masses 
Mor03u Signal 03 / unweighted (3D-MoRSE descriptors) 
G2u 2
nd
 component symmetry directional WHIM index / unweighted 
MATS8e Moran autocorrelation of lag 8 weighted by Sanderson electronegativity 
dipole moment (Debyes) To determine bond angles and the degree of polarity of covalent bonds 
G3m 3
rd
 component symmetry directional WHIM index / weighted by mass 
H7m H autocorrelation of lag 7 weighted by mass 
R6m R autocorrelation of lag 6/weighted by atomic masses 
 
Then, leave one out (LOO) cross validation was performed on models 10-15 since these models have coefficients of 
determination larger than 0.6 [31]. The results of LOO cross validation are summarized in Table S2 in the supporting 
information. This table shows that the cross-validation coefficient of determination (R
2
CV) has positive values starting from 
model 10 to model 15. Table S2 shows also those models 14 and 15, have the highest R
2
 and R
2
cv values as well as the 
lowest root mean square error (RMSE) values. Also, PRESS/SST is less than 0.4 for these models. Thus, models 14 and 
15 were chosen for further analysis with ANN. 
3.2 PCA 
The inputs of the ANN were the subset of the descriptors used in different MLR models (Table 1). First, PCA was 
performed to classify the molecules into training (60%), validation (20%)  and test (20%) sets. Figure 1 shows the first and 
second PC‘s for the factor spaces of the descriptors and COX-2 inhibitory activity data. According to the pattern of the 
distribution of the data in factor spaces (Figure 1), the training, validation and test sets molecules were selected 
homogenously so that molecules in different zones of Figure 1 belong to the three subsets. As we can also see from figure 
1 that compounds number 37 and 41 are outliers, which mean that those two compounds behave in a different way in 
comparison to the rest of other compounds with respect to activity and descriptors. Therefore, the total number of 
compounds now is 71 compounds.   The molecules subjected to the preliminary treatment mentioned previously, the 
classified data were used as an input for the ANN. 
3.3 ANN 
 In this study, a three-layered feed-forward ANN model with back propagation learning algorithm [32] was employed. At 
first, non-linear relationship between the subset of descriptors selected by stepwise selection-based MLR and COX-2 
inhibitory activity was preceded by ANN models with similar structure. The number of hidden layer's nodes was set to 7 for 
all models, and the number of nodes in the input layer was the number of descriptors.  
The correlation coefficients and cross-validation parameters of ANN analysis for ANN model numbers 14 and 15 are given 
in Table S3 in the supporting information. This table shows that the results of the two models are close to each other. 
However, model 14 seems to be better than model 15 since it has higher correlation coefficient for the test set as well as 
lower relative standard error of prediction.  
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To optimize the performance of the ANN models 14 and 15, these models were trained using different number of hidden 
nodes up to 20. Choosing the best model was based on cross-validation parameters and determination of minimum 
prediction error [33]. For the evaluation of the predictive ability of a multivariate calibration model, RMSEP is an important 
statistical parameter to find the best number of hidden nodes. Moreover, because large numbers of hidden nodes often 
draw attention to the risk of overfitting [34], considering models with low prediction error is avoided if a large number of 
hidden nodes are used in their network training. 
The results of optimizing the number of hidden nodes for models 14 and 15 are summarized in table S4 and table S5 in 
the supporting information respectively.  
Figure 2 shows the PRESS values against the number of hidden nodes as well as the regression factor against number of 
hidden nodes for model 14 and 15. This figure shows that the lowest PRESS (4.727) is obtained when using 7 hidden 
nodes for model 15 with regression coefficient for the test set of 0.823. For model 14, the lowest PRESS (5.928) is 
obtained when using 12 hidden nodes with regression coefficient for the test set of 0.757. 
 
Figure 2. PRESS against number of hidden nodes as well as regression factor against number of hidden nodes 
for model 14 and 15 respectively. 
Randomization test is performed to investigate the probability of chance correlation for the optimal models (models 14 and 
15 with 12 and 7 hidden nodes in the network, respectively). Chance correlation was done using the same configuration 
parameters and the same activation functions of all our ANN models. The results of chance correlation for models 14 
(using 12 hidden nodes) and 15 (using 7 hidden nodes) are summarized in Tables S6 and S7 in the supporting 
information, respectively. These tables show that the coefficients of determination obtained by chance are low in general 
while the RMSE values are high. This indicates that the models obtained from ANN are better than those obtained by 
chance. As we can see, our models were validated by calculating different statistical parameters, using external test set 
and finally performing randomization test. 
Figure 3 shows plot of the predicted activity against observed ones for the training and test sets compounds as well as 
their residuals for models 14 and 15 
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Figure 3.  Predicted inhibitory activities against observed ones and their residuals for model 14 and 15 
respectively. 
The correlation between calculated and observed pIC50  for the training set of model 14 is given by: 
Calculated pIC50 = 0.534 Observed pIC50 + 2.783   (1) 
And for the test set of this model is given by: 
Calculated pIC50 = 0.4252 Observed pIC50 + 3.486                (2) 
While the Correlation between calculated and observed pIC50 for the training set of model 15 is given by: 
Calculated pIC50 = 0.432 Observed pIC50 + 3.393   (3) 
And for the test set of this model is given by: 
Calculated pIC50 = 0.503 Observed pIC50 + 3.80   (4) 
 
To check the presence of more outliers in a model, for the training and test sets, the standard deviation of the observed 
activity data was calculated. The residue which is equal to the difference between the predicted and observed one were 
calculated also. Finally, if the value of the residue is larger than two times the standard deviation of the observed activity, 
then this point is considered as an outlier. We found that there was no outlier in our data. 
4. COMPARISON WITH OTHER QSAR STUDIES  
Few QSAR studies [35-40] have been performed on COX-2 inhibitors in the literature. But the data set of these studies 
was smaller than the data set used in our study. In these studies they used one core while in our study we used different 
cores and perform QSAR on the whole data without splitting them into cores or families. The previous studies used 3D-
QSAR and others used topological indicies while in our study we performed QSAR by applying  PC-ANN method and 
using pool of descriptors. Finally, our results indicate that the proposed models have better predictivity than the models 
proposed by other studies. Our models may be used to design new COX-2 inhibitors. 
Recently [41], we carried out a QSAR study of 48 tricyclic COX-2 inhinitors using MLR and PC-ANN. The results obtained 
by PC-ANN give advanced regression models with good prediction ability. 
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5. CONCLUSIONS  
MLR as well as ANN modeling method combined with the individual [30] factor selection approach is applied to predict the 
COX-2  inhibitory activity of a set of 73 non-tricyclic compounds. The results obtained by MLR shows that the best two 
models are close to each other with regression coefficient of 0.85.  These optimal models were further analyzed by PC-
ANN and the best model obtained was with regression coefficient of 0.823 for the test set. The lowest prediction sum of 
squares   (PRESS) value obtained for the prediction set is 4.727 which accounts for predictability of the model.. ANN 
provides improved models for heterogeneous data sets without splitting them into families and gives good regression 
models with good prediction ability. 
Generally, the models obtained from MLR analysis are better than those obtained by ANN analysis which may account for 
linear relation between the inhibitory activity of these 73 non-tricyclic inhibitors and descriptors. Both the external and 
cross-validation methods are used to validate the performances of the resulting models. Employed randomization test 
indicates that the models obtained from ANN are better than those obtained by chance. 
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Supplementary material 
Table S1. Molecular structures and observed inhibitory activities of the 73 non-tricyclic COX-2 inhibitors 
expressed as pIC50. 
 
Compound 
number 
Index *  R1 R2 p IC50  
 
1
C 
9a H SO2Me 6.09691 
2
C 
9b Me SO2Me 6.52287 
3
V
 9c F SO2Me 5 
4
C 
9d OMe SO2Me 5.30980 
5
C 
9e SO2Me H 6 
6
C 
9f SO2Me Me 6.52287 
7
C 
9g SO2Me F 6.22184 
8
C 
9h SO2Me OMe 5.49485 
 Ref 18 
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Compound  number Index * R1  R2 p IC50 
9
V
 11a H H 6.05060 
10
V
 11b F H 5.22184 
11
P
 11d H Me 6.49485 
12
V
 11e OH H 6.67778 
13
C 
11f OAc H 7.22184 
14
C 
12a H H 5.49485 
15
C 
12b F H 5.72124 
16
C 
12c OMe H 5.46852 
17
C 
12d H Me 6.49485 
18
V
 12e OH H 6.49485 
19
p
 12f OAc H 7.30102 
20
C 
13b F H 6.49485 
21
P
 13c OMe H 5.31875 
22
V
 13d H Me 4.50031 
23
C 
13e OH H 5.45593 
24
C 
13f OAc H 6.85387 
*Ref 19 
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Compound 
Number 
Index * R p IC50 
25
P
 9a 4-H 5.52287 
26
V
 9b 4-Br 5.44369 
27
P
 9c 4-F 4.44369 
28
V
 9d 4-OH 5.27572 
29
C 
9e 4-OMe 5.72124 
30
C 
9f 4-OAc 5.53760 
31
C 
9g 4-NHAc 5.60205 
32
C 
9h 3-Br 6.50863 
*Ref 20 
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Compound 
Number 
Index * R 1 R2 p IC50  
33
C 
12 --- ---- 6.00966 
34
C 
14 --- --- 7.92081 
35
C 
17a H H 6.08092 
36
C 
17c F F 6 
37
out 
17d OCH(CH3)2 H 5.50031 
38
C 
19 SO2CH3 H 4.50168 
39
C 
20a H --- 5.75448 
40
V
 20b F --- 5.81815 
41
out 
20c OCH(CH3)2 --- 6.82390 
42
C 
20e SO2CH3 --- 5.94309 
*Ref 21 
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Compound 
Number 
Index * R 1 R2 R3 p IC50 
43
V
 11 SO2NHCOCH3 ---- ---- 6.60205 
44
C 
19a H H ---- 7.52287 
45
V
 19c F F ---- 7.06048 
46
P
 20a H H H 5.92081 
47
C 
20b F H H 5.42021 
48
P
 20c F F H 6.11350 
49
C 
20d SO2CH3 H H 6.52287 
*Ref 22 
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Compound 
Number 
Index * R 1 R2 p IC50  
50
P
 7a NHSO2Me H 6.49485 
51
C 
7b NHSO2Me Me 6 
52
C 
7d NHSO2Me O Me  5 
 Ref 23 
 
 
Compound 
number 
Index * R  R1 p IC50 
53
V
 9c OMe H 5.16749 
54
P
 9d OH H 4.48678 
55
P
 9e F H 6.52287 
56
V
 10a H H 6.34678 
57
V
 10b H Me 5.49485 
58
P
 10c OMe H 5.69897 
59
C 
10d F H 5.16749 
60
P
 11b H Me 4.49485 
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*Ref 24 
 
Compound 
Number 
Index * R Het p IC50 
61
C
 20 4-SO2NH2 2-Pyridyl 6.52287 
62
C 
21 4-SO2NH2 4-Pyridyl 4.57186 
63
P
 22 4-SO2NH2 3-Me-2-Pyridyl 7.154901 
64
C 
23 2-SO2CH3 2-Pyridyl 6.67778 
65
C 
24 2-SO2CH3 3-Pyridyl 4.50031 
66
P
 25 2-SO2CH3 4-Pyridyl 6.95860 
67
C 
26 2-SO2CH3 3-Me-2-Pyridyl 6.37675 
68
C 
27 3-SO2CH3 2-Pyridyl 6.69897 
69
C 
28 3-SO2CH3 3-Pyridyl 4.49620 
70
C 
29 3-SO2CH3 4-Pyridyl 6.49485 
71
C 
30 4-SO2CH3 2-Pyridyl 6.48148 
72
C 
31 4-SO2CH3 3-Pyridyl 7.39794 
73
C 
 (Aspirin)  --- 5.61978 
 
*Ref 25 
C 
Compounds classified in the training or calibration set, 
P
 compounds classified in the external test set (prediction 
set), 
V 
compounds classified in the validation set. 
Out
 compounds classified as outliers. 
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Table S2. LOO cross validation parameters for the final MLR models 10-15 
 
 
 
 
 
 
 
 
 
 
 
 
R
2
cv is cross-validated correlation coefficient 
RSEP is relative standard error of prediction  
PRESS is predictive residual sum of squares  
SPRESS is uncertainty of prediction  
 
Table S3. Correlation coefficients and cross validation parameters for ANN models 14 and 15. 
 
Table S4. Correlation coefficients and cross validation parameters for optimizing number of hidden nodes for model 14. 
Hn. 
No. 
nPCs  R_train          PRESS_t
rain       
R2CV_
train          
R_test         PRESS_ 
test       
RSEP_ 
test      
R_val           PRESS_ 
val        
RSEP_ 
val     
6 6 0.675 14.846 -0.401 0.656 7.158 11.922 0.662 4.35 9.541 
7 6 0.689 14.597 -0.638 0.689 7.184 11.944 0.689 4.086 9.247 
8 6 0.654 16.33 -1.656 0.66 7.682 12.351 0.665 4.957 10.185 
9 6 0.666 15.166 -0.107 0.654 7.251 11.999 0.655 4.263 9.445 
10 6 0.741 12.175 0.074 0.702 6.293 11.178 0.658 4.439 9.639 
11 6 0.733 12.833 -0.289 0.738 6.042 10.953 0.658 4.382 9.577 
12 6 0.778 10.827 0.141 0.757 5.928 10.849 0.661 4.45 9.651 
13 6 0.684 14.324 -0.211 0.733 6.096 11.002 0.662 4.746 9.966 
14 6 0.737 13.082 -0.395 0.696 6.775 11.599 0.651 4.323 9.512 
15 6 0.744 12.026 0.06 0.652 7.52 12.22 0.69 4.384 9.578 
16 6 0.675 14.648 -0.418 0.77 5.602 10.547 0.717 3.892 9.025 
17 6 0.756 11.527 0.288 0.718 6.035 10.947 0.686 4.207 9.383 
Model 
 
PRESS SPRESS SST R
2
CV PRESS/SST PSE RSEP   
10 18.438 0.545 29.608 0.377 0.623 0.503 8.36 
11 17.366 0.534 30.680 0.434 0.566 0.488 8.113 
12 15.592 0.51 32.455 0.52 0.480 0.462 7.688 
13 14.391 0.494 33.656 0.572 0.428 0.444 7.386 
14 13.502 0.483 34.545 0.609 0.391 0.43 7.154 
15 13.502 0.478 34.545 0.609 0.391 0.43 7.154 
Model 
No. 
hn
. 
nP
Cs 
R_tra
in          
PRES
S_trai
n       
SSR_t
rain         
R2CV_
train          
R_test         PRESS
_test       
RSEP_
test      
R_val           PRES
S_val        
RSEP
_val      
14 7 6 0.706 13.842 9.028 -0.533 0.755 6.020 10.933 0.688 4.166 9.337 
15 7 6 0.666 14.965 10.646 -0.406 0.726 6.294 11.179 0.660 4.378 9.572 
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18 6 0.715 13.822 -0.624 0.748 5.573 10.519 0.65 4.329 9.518 
19 6 0.665 15.19 -0.64 0.666 6.925 11.726 0.652 4.3 9.486 
20 6 0.653 15.859 -0.488 0.728 6.728 11.558 0.653 4.486 9.689 
 
 
Table S5. Correlation coefficients and cross validation parameters for optimizing number of hidden nodes for model 15. 
 
 
hn. 
NO 
nP
Cs 
R_tra
in          
PRESS_t
rain       
R2CV_t
rain          
R_test         PRESS
_test       
RSEP_t
est                 
R_val PRESS_
val        
RSEP_
val      
5 6 0.670 16.033 -1.023 0.706 6.835 12.171 0.706 3.241 8.702 
6 6 0.705 14.782 -0.681 0.710 6.616 11.974 0.663 3.538 9.092 
7 6 0.730 13.707 -0.392 0.823 4.727 10.122 0.711 3.109 8.522 
8 6 0.653 16.133 -0.510 0.772 5.841 11.251 0.689 3.441 8.967 
9 6 0.754 12.506 -0.027 0.687 6.617 11.975 0.681 3.246 8.709 
10 6 0.692 14.677 -0.108 0.687 6.878 12.209 0.660 3.550 9.108 
11 6 0.680 16.342 -1.156 0.707 6.417 11.792 0.700 3.269 8.739 
12 6 0.662 16.359 -1.116 0.714 3.570 0.726 0.682 3.553 9.112 
13 6 0.659 16.020 -0.609 0.755 5.797 11.209 0.706 3.417 8.936 
14 6 0.665 15.791 -0.407 0.818 4.685 10.076 0.688 3.004 8.378 
15 6 0.664 15.826 -0.459 0.725 5.867 11.276 0.651 3.745 9.354 
16 6 0.717 13.921 -0.185 0.755 5.348 10.766 0.690 3.078 8.481 
17 6 0.754 12.343 0.015 0.794 5.175 10.590 0.670 3.464 8.997 
18 6 0.756 12.129 0.112 0.723 7.075 12.383 0.656 4.319 10.046 
19 6 0.687 15.048 -0.062 0.654 7.020 12.334 0.705 2.940 8.289 
20 6       0.70
0   
 14.476      -0.116      0.688       6.626     11.984      0.687     
  
3.220        8.674    
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Table S6. Correlation coefficients and cross validation parameters for chance correlation results for model 14 
with 12 hidden nodes. 
Trial 
No. 
nP
Cs      
R_train           PRES_ 
train        
R2CV_ 
train           
R_test          PRESS
_test        
R_val            PRESS_ 
val         
R2CV_ 
val            
1 6 -0.019 62.21 -5.066 -0.116 3.189 -0.006 3.688 -22.013 
2 6 0.137 51.255 -3.072 -0.093 2.474 0.157 2.799 -2.102 
3 6 -0.061 69.5 -2.482 -0.042 2.849 -0.263 3.043 -7.338 
4 6 0.122 51.381 -3.347 -0.047 1.384 0.397 1.398 -20.447 
5 6 -0.200 57.773 -8.684 0.249 1.107 -0.036 2.357 -6.273 
6 6 -0.176 71.111 -3.402 -0.191 2.456 -0.258 3.464 -1.861 
7 6 -0.188 80.24 -3.445 -0.165 2.329 -0.154 2.215 -4.958 
8 6 -0.193 58.657 -9.458 0.152 2.347 0.275 2.895 -4.784 
9 6 0.218 51.558 -2.354 -0.147 1.647 0.268 1.54 -2.466 
10 6 0.193 46.683 -4.436 -0.177 1.37 0.288 1.522 -17.426 
 
 
Table S7. Correlation coefficients and cross validation parameters for chance correlation results for model 15 
with 7 hidden nodes. 
Trial 
No. 
nP
Cs 
R_train          PRESS_tr
ain       
R2CV_tr
ain          
R_test         PRESS_t
est       
R_val          PRESS_
val        
R2CV_val           
1 6 -0.028 57.208 -4.349 -0.017 1.273 -0.232 2.308 -11.600 
2 6 0.076 51.222 -5.105 -0.225 2.609 -0.162 2.143 -5.870 
3 6 0.092 110.310 -8.014 -0.112 10.131 -0.043 11.265 -102.793 
4 6 0.149 45.089 -11.099 -0.686 1.727 0.155 1.540 -18.123 
5 6 0.128 45.614 -13.166 -0.225 1.316 -0.144 1.634 -77.889 
6 6 -0.298 57.911 -12.601 -0.228 1.547 0.253 1.652 -34.570 
7 6 -0.166 61.472 -5.667 0.142 1.541 0.142 1.561 -11.975 
8 6 -0.183 62.800 -6.189 -0.196 2.330 0.283 2.121 -5.291 
9 6 -0.102 60.916 -4.952 -0.134 1.407 -0.166 2.858 -20.457 
10 6 0.271 45.575 -2.472 0.151 2.093 0.281 2.435 -9.185 
 
